IN8bio

IN8bio, Inc. is a clinical-stage biotechnology company based in New York that specializes in developing innovative therapies for cancer treatment, utilizing gamma-delta T cells. These immune cells possess unique properties that allow them to differentiate between healthy and diseased tissues. The company is currently conducting two Phase 1 clinical trials for its lead product candidates: INB-200, a genetically modified autologous gamma-delta T cell therapy aimed at treating newly diagnosed glioblastoma, and INB-100, an allogeneic therapy for patients with acute leukemia undergoing hematopoietic stem cell transplantation. IN8bio also has a diverse portfolio of preclinical programs targeting various solid tumor types, further expanding its commitment to advancing cell-based immunotherapies. Founded in 2016 and previously known as Incysus Therapeutics, IN8bio continues to focus on harnessing the potential of gamma-delta T cells to improve cancer treatment outcomes.